推荐产品
產品線
MISSION®
儲存溫度
−20°C
基因資訊
正在寻找类似产品? 访问 产品对比指南
一般說明
Each MISSION shRNA clone is constructed within the lentivirus plasmid vector, pLKO.1-Puro, followed by transformation into Escherichia coli. The pLKO.1-Puro vector contains bacterial (ampicillin) and mammalian (puromycin) antibiotic resistance genes for selection of inserts in either bacterial or mammalian cell lines. Each clone set consists of an average of 3-5 constructs that have been designed against each target gene using a proprietary algorithm. Therefore, a range of knockdown efficiency, with at least one construct from each gene set being >70%, can be expected when using these clones. This allows one to examine the effect of loss of gene function over a large series of gene knockdown efficiencies. Each shRNA construct has been cloned and sequence verified to ensure a match to the target gene.
For a detailed listing of other available gene family sets, visit the gene family set website.
Sequenced-verified shRNA lentiviral plasmids (pLKO.1-puro) are provided as purified plasmid DNA suitable for virus production and transient transfection. DNA is provided in 40 μl aliquots per well in Tris,EDTA (TE) solution. An average of 2 μg per clone is provided per well with a range from 400 ng to 4 μg. The set comes in 96-well plates that are barcoded for simple identification. A CD containing RefSeq, gene description, gene symbol, clone ID, hairpin sequence, locus link, and plate map positions are provided with the gene family set.
其他說明
Number of Genes: 618, Number of Clones: 3916
The exact gene and clone count at time of purchase may vary slightly as the TRC library is continually updated.
法律資訊
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
10 - Combustible liquids
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
David Murdoch et al.
Current opinion in oncology, 20(1), 104-111 (2007-11-29)
(1) Many of the significant advances in cancer management in recent years have centered on the development and introduction of molecularly targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors.(2) Despite targeted therapy that has clearly benefited and even
Virendra S Gomase et al.
Current drug metabolism, 9(3), 255-258 (2008-03-14)
Kinomics is derived from the word kinome that is the kinase part of the proteome. Kinomics is a merger between genomics and proteomics. Defining the kinase complement of the human genome, the kinome, has provided an excellent starting point for
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门